Originally Posted by
SylvesterCat
I think that is all 'priced in' bull. No surprise to anyone, and certainly no different to any of the 5 listed operators. Referring back to my own commentaries, its pretty clear that SUM firms more exposed to 'development' activity as a source of their NPAT will take a harder hit. I still believe resales will be impacted also by a drop in value, albeit to a lesser extent. Fortunately for ARV (and RYM, although they are pricier shares), they have a nice 'balance' between development, resales and care.